Publications in collaboration with researchers from Hospital Alto Guadalquivir (8)

2023

  1. Patients With High Cardiovascular Risk as Candidates to Bempedoic Acid, After Treatment With Statins, Ezetimibe and PCSK9 Inhibitors: An Estimation and Cost-Effectiveness Analysis

    Journal of cardiovascular pharmacology, Vol. 81, Núm. 1, pp. 70-75

2022

  1. Clinical Features and Risk Factors for Mortality Among Long-term Care Facility Residents Hospitalized Due to COVID-19 in Spain

    Journals of Gerontology - Series A Biological Sciences and Medical Sciences, Vol. 77, Núm. 4, pp. E138-E147

  2. Does admission acetylsalicylic acid uptake in hospitalized COVID-19 patients have a protective role? Data from the Spanish SEMI-COVID-19 Registry

    Internal and Emergency Medicine, Vol. 17, Núm. 3, pp. 761-775

  3. Effect of PCSK9 inhibitors on remnant cholesterol and lipid residual risk: The LIPID-REAL registry

    European Journal of Clinical Investigation, Vol. 52, Núm. 12

  4. Sex Differences in Low-Density Lipoprotein Cholesterol Reduction with PCSK9 Inhibitors in Real-world Patients: The LIPID-REAL Registry

    Journal of Cardiovascular Pharmacology, Vol. 79, Núm. 4, pp. 523-529

2021

  1. Evolution of the use of corticosteroids for the treatment of hospitalised COVID-19 patients in Spain between March and November 2020: SEMI-COVID national registry

    Journal of Clinical Medicine, Vol. 10, Núm. 19

  2. Healthcare workers hospitalized due to COVID-19 have no higher risk of death than general population. Data from the Spanish SEMI-COVID-19 Registry

    PLoS ONE, Vol. 16, Núm. 2 February

2015

  1. Two-week, high-dose proton pump inhibitor, moxifloxacin triple Helicobacter pylori therapy after failure of standard triple or non-bismuth quadruple treatments

    Digestive and Liver Disease, Vol. 47, Núm. 2, pp. 108-113